Lauren Bonner, MD
Psychiatry · Scottsdale, AZNPI 1740265990
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $37,831 of the $44,084 with a category attached, or 85.8%. Otsuka America Pharmaceutical, Inc. accounts for 92.5% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $27,135 and has fallen 95.0% since, to $1,365 in 2025. Among psychiatry clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 116 payments — averaging $380.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$41K
- Alkermes, Inc.$2K
- AbbVie$247
- Otsuka Pharmaceutical Development & Commercialization, Inc.$239
- Teva Pharmaceuticals USA, Inc.$119
- Neurocrine Biosciences, Inc.$70
- plus $310 from 9 others
What the payments were for
- Speaking & faculty fees$37,83186%
- Travel & lodging$3,9329%
- Food & beverage$2,2525%
- Education$690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 66 | $40,790 |
| Alkermes, Inc. | 14 | $2,310 |
| AbbVie(2 entities) | 12 | $247 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $239 |
| Teva Pharmaceuticals USA, Inc. | 3 | $119 |
| Neurocrine Biosciences, Inc. | 4 | $70 |
| Johnson & Johnson | 3 | $59 |
| Vanda Pharmaceuticals Inc. | 2 | $56 |
| Alpha Cognition USA, Inc. | 1 | $51 |
| Indivior Inc. | 2 | $31 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Medtronic | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Shire North American Group Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$39,829
- LYBALVI$5,268
- ARISTADA$3,200
- ARISTADA INITIO$800
How this compares
$44,084 in reported general payments places this provider in the 95th percentile of 573 psychiatry providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 14 | $79,325 |
| AristadaAripiprazole Lauroxil | 12 | $27,122 |
| TrintellixVortioxetine Hydrobromide | 11 | $6,176 |
| Naltrexone Hcl | 22 | $3,793 |
| Bupropion XlBupropion Hcl | 124 | $3,605 |
| Memantine Hcl | 53 | $2,435 |
| Quetiapine Fumarate | 105 | $1,864 |
| Mirtazapine | 58 | $1,733 |
| Duloxetine Hcl | 64 | $1,530 |
| Trazodone Hcl | 90 | $1,286 |
| Aripiprazole | 20 | $1,088 |
| Bupropion Hcl SrBupropion Hcl | 24 | $933 |
| Gabapentin | 30 | $838 |
| Fluoxetine Hcl | 14 | $781 |
| Lamotrigine | 47 | $684 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $119 | $79,32514 claims |
| Alkermes, Inc.Aristada | $2,310 | $27,12212 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $25 | $6,17611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 573 psychiatry providers in Arizona.
Other psychiatry in Scottsdale
- Henry SchulteScottsdale$77K
- Lois KrahnScottsdale$32K
- Alvin BursteinScottsdale$18K
- Marie GronleyScottsdale$8K
- Alpa SanghviScottsdale$6K
- Adam KoelschScottsdale$5K
- Elizabeth RotellaScottsdale$4K
- Supriya NairScottsdale$4K
- Paul ValbuenaScottsdale$4K
- Jason CaplanPhoenix$999K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.